Celleo is pleased to announce the appointment of Mr Brett Burns to the company’s Board as Non-Executive Director. Celleo also thanks Mr Gordon Naylor for his shaping role as NED, following his resignation as he takes on Chair responsibilities at CSL Seqirus ahead of its demerger from CSL.

“I’m thrilled to welcome Brett to Celleo’s Board,” announced David Kneen, CEO and Managing Director. “His dynamism and deep corporate governance experience is a powerful addition to Celleo at this exciting time, as we commence product deliveries to global customers in 2026.”

Mr Brett Burns is an experienced NED with over 25 years’ expertise across corporate governance, M&A, capital markets, and strategic growth, with a background in corporate law and governance. He brings extensive ASX-listed and private board experience, including chairing remuneration committees, guiding international expansion, and navigating complex transactions and regulatory environments.

Mr Gordon Naylor served on Celleo’s Board as NED since its founding and has been instrumental in developing the company’s robust financial, strategic and operational foundations. He stepped down from Celleo’s Board after his nomination as Chair of CSL Seqirus. In August, global biotherapeutics leader CSL announced its intention to demerge CSL Seqirus as a substantial ASX-listed entity and global influenza vaccine leader before the end of Financial Year 2026. Mr Gordon Naylor is a former President and CFO of Seqirus.

“Gordon’s contribution to Celleo’s journey has been fundamental in building the company’s strength.” noted David Kneen. “We wish Gordon every success in his role at CSL Seqirus, and extend our gratitude for his guidance at Celleo.”

Celleo develops Intelligent Production Systems for Cell Therapy. The company will commence delivery of GMP systems to leading biotherapeutics customers in the USA, Canada, European Union, UK and Australia in 2026.

Mr Brett Burns	Mr Gordon Naylor